VINEETLABPharmaceuticals
Vineet Laboratories Ltd — Profit & Loss Statement
₹29.06
+0.00%
Vineet Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -8425.44 | 0.00 | — |
| Tax Rate For Calcs | 0.03 | 0.30 | 0.38 | 0.29 | — |
| Normalized EBITDA | -14.30 Cr | 7.66 Cr | 7.06 Cr | 12.85 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Reconciled Depreciation | 2.50 Cr | 2.52 Cr | 2.37 Cr | 2.02 Cr | — |
| Reconciled Cost Of Revenue | 70.24 Cr | 113.92 Cr | 176.55 Cr | 153.67 Cr | — |
| EBITDA | -14.30 Cr | 7.66 Cr | 7.06 Cr | 12.85 Cr | — |
| EBIT | -16.80 Cr | 5.14 Cr | 4.69 Cr | 10.83 Cr | — |
| Net Interest Income | -3.98 Cr | -4.78 Cr | -3.26 Cr | -1.92 Cr | — |
| Interest Expense | 3.98 Cr | 4.78 Cr | 2.66 Cr | 1.49 Cr | — |
| Normalized Income | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Net Income From Continuing And Discontinued Operation | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Total Expenses | 93.78 Cr | 145.91 Cr | 206.67 Cr | 180.03 Cr | — |
| Diluted Average Shares | 0.92 Cr | 0.93 Cr | 0.92 Cr | 0.92 Cr | — |
| Basic Average Shares | 0.92 Cr | 0.93 Cr | 0.92 Cr | 0.92 Cr | — |
| Diluted EPS | -21.90 | 1.11 | 1.36 | 7.16 | — |
| Basic EPS | -21.90 | 1.11 | 1.36 | 7.16 | — |
| Diluted NI Availto Com Stockholders | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Net Income Common Stockholders | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Net Income Including Noncontrolling Interests | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Net Income Continuous Operations | -20.19 Cr | 1.03 Cr | 1.25 Cr | 6.64 Cr | — |
| Tax Provision | -0.58 Cr | -0.66 Cr | 0.78 Cr | 2.71 Cr | — |
| Pretax Income | -20.78 Cr | 0.36 Cr | 2.03 Cr | 9.35 Cr | — |
| Other Non Operating Income Expenses | 1.99 Cr | 0.46 Cr | 0.12 Cr | 0.03 Cr | — |
| Net Non Operating Interest Income Expense | -3.98 Cr | -4.78 Cr | -3.26 Cr | -1.92 Cr | — |
| Interest Expense Non Operating | 3.98 Cr | 4.78 Cr | 2.66 Cr | 1.49 Cr | — |
| Operating Income | -18.78 Cr | 4.68 Cr | 5.63 Cr | 11.15 Cr | — |
| Operating Expense | 23.54 Cr | 31.99 Cr | 30.12 Cr | 26.36 Cr | — |
| Other Operating Expenses | 15.70 Cr | 23.09 Cr | 12.25 Cr | 11.57 Cr | — |
| Depreciation And Amortization In Income Statement | 2.50 Cr | 2.52 Cr | 2.37 Cr | 2.02 Cr | — |
| Depreciation Income Statement | 2.50 Cr | 2.52 Cr | 2.37 Cr | 2.02 Cr | — |
| Gross Profit | 4.76 Cr | 36.67 Cr | 35.75 Cr | 37.51 Cr | — |
| Cost Of Revenue | 70.24 Cr | 113.92 Cr | 176.55 Cr | 153.67 Cr | — |
| Total Revenue | 75.00 Cr | 150.59 Cr | 212.29 Cr | 191.17 Cr | — |
| Operating Revenue | 75.00 Cr | 150.59 Cr | 212.29 Cr | 191.17 Cr | — |
| Total Unusual Items | — | 0.36 Cr | -22000.00 | 0.00 | 0.00 |
| Total Unusual Items Excluding Goodwill | — | 0.36 Cr | -22000.00 | 0.00 | 0.00 |
| Interest Income | — | 0.04 Cr | 0.12 Cr | 0.16 Cr | 0.05 Cr |
| Rent Expense Supplemental | — | 0.04 Cr | 0.02 Cr | 0.05 Cr | 0.03 Cr |
| Special Income Charges | — | 0.36 Cr | 0.00 | 0.00 | 0.00 |
| Other Special Charges | — | -0.36 Cr | — | — | — |
| Total Other Finance Cost | — | 0.93 Cr | 0.72 Cr | 0.60 Cr | 0.61 Cr |
| Interest Income Non Operating | — | 0.04 Cr | 0.12 Cr | 0.16 Cr | 0.05 Cr |
| Selling General And Administration | — | 3.49 Cr | 4.04 Cr | 2.40 Cr | 0.65 Cr |
| Selling And Marketing Expense | — | 2.53 Cr | 2.55 Cr | 1.42 Cr | 0.24 Cr |
| General And Administrative Expense | — | 0.96 Cr | 1.49 Cr | 0.97 Cr | 0.41 Cr |
| Rent And Landing Fees | — | 0.04 Cr | 0.02 Cr | 0.05 Cr | 0.03 Cr |
| Amortization | — | — | — | 0.00 | 0.00 |
| Net Income Discontinuous Operations | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vineet Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.